Amgen Faces $400M+ Liability to Regeneron Following Antitrust Ruling on Cholesterol Drug
Amgen, a prominent biotechnology company based in Thousand Oaks, California, faces potential financial ramifications exceeding $400 million following a significant antitrust lawsuit concerning its cholesterol-lowering medication. The outcome of this legal battle could have substantial consequences for both Amgen and its competitor Regeneron Pharmaceuticals. The lawsuit, which centered on allegations of anti-competitive practices, has drawn attention to the ongoing efforts within the pharmaceutical industry to navigate regulatory frameworks while maintaining competitive pricing for consumers. The jury’s decision in favor of Regeneron underscores the legal challenges that can arise when companies seek to protect their market … Read more